AavantiBio and Resilience Announce Strategic Collaboration for Gene Therapy Development and Manufacturing
UF startup and UF Innovate | The Hub resident AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, and National Resilience, Inc. (Resilience), a company building the world’s most advanced biopharmaceutical manufacturing ecosystem and who recently acquired UF startup and UF Innovate | Sid Martin Biotech alum Ology Bioservices, announced a strategic collaboration to support the development and manufacturing of AavantiBio’s pipeline of therapies, including its lead program in Friedreich’s Ataxia (FA).
Genascence Announces Completion of Dosing and Interim Safety Data for Phase 1 Clinical Trial of GNSC-001 in Osteoarthritis
Genascence Corporation, a clinical-stage biotechnology company developing life-changing gene therapy products for prevalent musculoskeletal diseases, announced that dosing across all three cohorts has been completed in Phase 1 clinical trial of GNSC-001 for the treatment of osteoarthritis (OA).
Parent Project Muscular Dystrophy Awards $348,891 Grant to University of Florida Wellstone Center
Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy, awarded the University of Florida Wellstone Muscular Dystrophy Cooperative Center a grant for $348,891.
University of Florida Health Ophthalmology Researcher Awarded Prestigious Prize for Pioneering Work
University of Florida Health ophthalmology researcher William W. Hauswirth, Ph.D., whose long and distinguished career includes developing and testing treatments for multiple forms of genetic blindness, is among the scientists being recognized for their pioneering work to eradicate vision loss.
Dr. Barry Byrne Receives “See the Light” Award From the Mathew Forbes Romer Foundation
For families facing a devastating diagnosis of pediatric neurodegenerative genetic disease, Barry Byrne, M.D., Ph.D., provides a sense of hope and possibility. As director of the Powell Gene Therapy Center, the associate chair of pediatrics and the Earl and Christy Powell University Chair in Genetics at the University of Florida, Byrne has made significant contributions […]
Unraveling Genetic Mutations
Listen to Shannon Boye, Ph.D., an associate professor of pediatrics at the University of Florida, talk about her journey in academia and what led her to try gene therapy in the fight against a mutation causing babies to be born blind. Learn more about Unraveling Genetic Mutations.
Dr. Barry Byrne Featured in Denison Magazine
Barry J. Byrne, M.D., Ph.D., director of the University of Florida Powell Gene Therapy Center, a professor in Pediatrics and Molecular Genetics & Microbiology, and the associate chair in Pediatrics at the University of Florida, is studying a variety of rare diseases with specific attention to developing therapies for inherited muscle disease. His development of the Powell Gene […]
UF Researcher Among 2020 ASGCT Award Recipients
Mavis Agbandje-McKenna, Ph.D., a professor of Biochemistry and Molecular Biology at the University of Florida College of Medicine, is among the winners of 2020 Outstanding Achievement Award (OAA) which recognizes an American Society of Gene & Cell Therapy (ASGCT) Member who has achieved a pioneering research success, specific high-impact accomplishment, or a lifetime of significant […]
RTP Gene Tech Firm Lands Deal Worth Up to $90M for 8 Nervous System Therapies
StrideBio, a life science startup focused on gene-editing technology, has a deal in place with a Massachusetts drug firm that could be worth nearly $90M plus royalties in years to come for rights to as many as eight potential gene-based therapies. Any developed drug would focus on the central nervous system and neuromuscular “targets,” StrideBio […]
U of Florida and Penn Ink Licensing Deal for Gene Therapy to Treat Retinal Disease (Tech Transfer eNews Blog)
Biotech company Ophthotech Corporation has entered into an exclusive global license agreement with the University of Florida Research Foundation (UFRF) and the University of Pennsylvania (Penn) to commercialize a treatment for a disease that causes blindness. The licensed technology is an adeno-associated virus (AAV) gene therapy to treat rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP), an […]